A Proof-Of-Concept Phase 1b/2a Randomized, Vehicle, and Comparator-Controlled Study of Topical DLQ01 to Assess the Safety and Efficacy in the Treatment of Androgenetic Alopecia (AGA) in Men

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 18 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DLQ-01 (Primary) ; DLQ-01 (Primary) ; Minoxidil; Prostaglandin F2 alpha agonists
Indications Alopecia; Male pattern baldness
Focus Proof of concept; Therapeutic Use
Sponsors Dermaliq Therapeutics

16 Jul 2024 According to a Dermaliq Therapeutics media release, Prof. Rodney Sinclair, MD is principal investigator in this trial. The trial was conducted at Sinclair Dermatology, Melbourne Australia. Data from this trial will be published in a peer reviewed journal in the near future.
16 Jul 2024 Primary endpoint has been met. (TAHC (total, terminal, and vellus) [ Time Frame: 28 weeks ]), according to a Dermaliq Therapeutics media release.
16 Jul 2024 Results published in the Dermaliq Therapeutics Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com